Ahmad Tuffaha

Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat

Dominique P. Germain, Derralynn Hughes, Daniel G. Bichet et al. · New England Journal of Medicine · 2016 · 556 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial

Raphael Schiffmann, Özlem Göker-Alpan, Myrl Holida et al. · Journal of Inherited Metabolic Disease · 2019 · 137 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy

Peter W. Santos, Jianghua He, Ahmad Tuffaha et al. · International Urology and Nephrology · 2017 · 40 citations

Medicine, Internal Medicine, Nephrology +16